Abstract
Child and adolescent psychiatry is a relatively young field and the recognition, classification, and treatment of disorders in children and adolescents lag behind those in adults. In recent years there is an increasing awareness of the differences between children and adults in psychopathology and pharmacology. Related to this new paediatric regulations have been introduced. This article reviews the regulatory and legislative measures that were adopted in the EU in 2007 and the subsequent impact of these measures on the field of paediatric psychopharmacology. The consequences of the paediatric regulation in the EU are reflected in several domains: regulatory, research aimed at drug development and clinical practices. In the regulatory domain, the consequences include: new paediatric indications, inclusion of special (class) warnings, specification of dose regimens, and information on safety specific to children and adolescents, and development of new medicinal formulations. The paediatric regulation leads to timely development of paediatric friendly formulations and better quality of the clinical evidence. In clinical practices, an increased awareness of the uniqueness of paediatric pharmacology is emerging among medical profes...Continue Reading
References
Jan 13, 1999·Pediatric Clinics of North America·J T WalkupB Geller
Mar 4, 2000·JAMA : the Journal of the American Medical Association·J M ZitoF Lynch
Jun 1, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·T A Ban
Aug 3, 2001·Pediatrics·E SchirmL T de Jong-van den Berg
Nov 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·L Eugene ArnoldElaine Tierney
Feb 28, 2004·BMJ : British Medical Journal·Macey L MurrayCorinne S de Vries
Apr 28, 2004·Lancet·Craig J WhittingtonEllen Boddington
Mar 3, 2005·Journal of Child and Adolescent Psychopharmacology·Benedetto Vitiello
May 14, 2005·BMJ : British Medical Journal·Macey L MurrayMary Thompson
May 21, 2005·European Journal of Clinical Pharmacology·H TobiR B Minderaa
Nov 22, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Tamar D WohlfarthJitschak G Storosum
Sep 5, 2007·Archives of General Psychiatry·Carmen MorenoMark Olfson
May 3, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·Luuk J KalverdijkLolkje T W de Jong-van den Berg
Oct 15, 2008·Current Opinion in Psychiatry·Michael KoelchJoerg M Fegert
Dec 10, 2008·Child and Adolescent Psychiatry and Mental Health·Benedetto Vitiello
Jan 9, 2009·Paediatric Drugs·Agnès Saint-Raymond, Nathalie Seigneuret
May 12, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Tamar WohlfarthChristine Gispen-de Wied
May 27, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Benedetto VitielloCelso Arango
Jun 17, 2009·The American Journal of Psychiatry·Madelyn S GouldThomas Cooper
Citations
Jan 20, 2012·Expert Opinion on Drug Delivery·Alejandro SosnikDiego A Chiappetta
Jun 15, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Celso Arango
May 16, 2015·Drug Discovery Today·Joris LangedijkMarie-Hélène D B Schutjens
Mar 25, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark J MillanSven Ove Ögren
Apr 4, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark J MillanSven Ove Ögren
Nov 30, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Celso Arango
Feb 22, 2014·Advanced Drug Delivery Reviews·M A TurnerUNKNOWN Global Research in Paediatrics
May 14, 2014·Advanced Drug Delivery Reviews·Alejandro Sosnik, Angel M Carcaboso
Jan 12, 2017·Paediatric Drugs·Gueorgui DubrocqB Ryan Phelps
Mar 31, 2021·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C M Díaz-CanejaC Arango